New drug combo aims to tame stubborn psoriatic arthritis
NCT ID NCT07280702
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding deucravacitinib to standard therapy helps adults with psoriatic arthritis that is not well controlled. About 128 participants will receive the combination and be monitored for 48 weeks. The goal is to reduce skin and joint symptoms and improve quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS (PSA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diabetes drugs tame joint inflammation in psoriatic arthritis?
- Could a common blood thinner shield psoriasis Patients' arteries?
- New biologic drug aims to ease joint pain and swelling in Tough-to-Treat psoriatic arthritis
- Neck scan could predict heart attacks in arthritis patients
- New study tracks psoriatic arthritis patients to predict joint damage
- Dietary formula shows promise for psoriatic arthritis symptom relief